Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP; NSC-107392), with special reference to its iron-chelating properties.
D000328:Adult; D001773:Blood Cells / Q000187:drug effects; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007501:Iron / Q000097:blood / Q000378:metabolism; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D007504:Iron Radioisotopes; D007938:Leukemia / Q000188:drug therapy; D009325:Nausea / Q000139:chemically induced; D013053:Spectrophotometry; D013882:Thiosemicarbazones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D007502:Iron Chelating Agents; D007504:Iron Radioisotopes; D013882:Thiosemicarbazones; D007501:Iron